Ming Ma, Ying Ma, Ling Ma
Department of Hepatobiliary Surgery, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang 830001, P.R. China.
Department of Clinical Laboratory, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830054, P.R. China.
Exp Ther Med. 2019 Aug;18(2):1196-1202. doi: 10.3892/etm.2019.7674. Epub 2019 Jun 14.
The present study aimed to investigate the role and underlying molecular mechanism of microRNA (miR)-125a-5p in hepatocellular carcinoma. The level of miR-125a-5p was detected using reverse transcription-quantitative polymerase chain reaction. TargetScan was used to investigate the association between miR-125a-5p and TP53-regulated inhibitor of apoptosis 1 (TRIAP1)/B cell lymphoma-2-like 2 protein (BCL2L2). Dual luciferase reporter assay was used to confirm this prediction. To investigate the role of miR-125a-5p in hepatocellular carcinoma (HCC) cells, miR-125a-5p was overexpressed in the human HCC cell line PLC/PRF/5 using miR-125a-5p mimics. Subsequently, cell proliferation, cell apoptosis and cell migration were studied using MTT assay, flow cytometry analysis and Transwell assay, respectively. Protein expression levels in the present study were measured by western blot analysis. Taken together, the present results suggested that miR-125a-5p was markedly downregulated in HCC cells. TRIAP1 and BCL2L2 were direct targets of miR-125a-5p and were upregulated in PLC/PRF/5 cells. miR-125a-5p upregulation inhibited PLC/PRF/5 cell viability and migration and induced cell apoptosis. In addition, miR-125a-5p overexpression increased the expression of caspase9 and apoptotic protease-activating factor 1. Notably, the present study revealed that all the effects on PLC/PRF/5 cells elicited by miR-125a-5p overexpression were eliminated by TRIAP1/BCL2L2 upregulation. In conclusion, miR-125a-5p was shown to be downregulated in hepatocellular carcinoma and its upregulation inhibited hepatocellular carcinoma cell growth and metastasis by targeting TRIAP1 and BCL2L2.
本研究旨在探究微小RNA(miR)-125a-5p在肝细胞癌中的作用及潜在分子机制。采用逆转录-定量聚合酶链反应检测miR-125a-5p的水平。使用TargetScan研究miR-125a-5p与TP53调控的凋亡抑制因子1(TRIAP1)/B细胞淋巴瘤-2样蛋白2(BCL2L2)之间的关联。采用双荧光素酶报告基因检测法验证这一预测。为了研究miR-125a-5p在肝癌(HCC)细胞中的作用,使用miR-125a-5p模拟物在人肝癌细胞系PLC/PRF/5中过表达miR-125a-5p。随后,分别采用MTT法、流式细胞术分析和Transwell法研究细胞增殖、细胞凋亡和细胞迁移。本研究中的蛋白质表达水平通过蛋白质印迹分析进行测定。综上所述,目前的结果表明miR-125a-5p在HCC细胞中显著下调。TRIAP1和BCL2L2是miR-125a-5p的直接靶标,且在PLC/PRF/5细胞中上调。miR-125a-5p上调抑制了PLC/PRF/5细胞的活力和迁移并诱导细胞凋亡。此外,miR-125a-5过表达增加了半胱天冬酶9和凋亡蛋白酶激活因子1的表达。值得注意的是,本研究表明,TRIAP1/BCL2L2上调消除了miR-加5a-5p过表达对PLC/PRF/5细胞产生的所有影响。总之,研究表明miR-125a-5p在肝细胞癌中表达下调,其上调通过靶向TRIAP1和BCL2L2抑制肝细胞癌细胞生长和转移。